Loading oncology approvals…
Loading oncology approvals…
Regulatory
Every record is one authority's decision for one application or DIN, shown with its jurisdiction, date, indication text as published and status. A molecule approved in one jurisdiction for one indication is not 'approved' in general.
RegulatoryDevelopment pipeline →Methodology
Coverage
Counts of records, not of drugs approved: one application can carry several dated records (original approval, efficacy supplements, one row per DIN in Canada).
Approval records
4,340
Distinct drugs
372
Records naming a cancer
982
Dated in the last 12 months
182
| Authority | Jurisdiction | Records | Drugs | In force | Withdrawn / cancelled | Last 12 months | Latest dated record |
|---|---|---|---|---|---|---|---|
| FDA | US | 2,343 | 304 | 2,343 | 0 | 115 | Sep 18, 2026 |
| Health Canada | CA | 1,538 | 273 | 979 | 559 | 49 | Sep 22, 2026 |
| EMA | EU | 459 | 245 | 385 | 74 | 18 | Jul 20, 2026 |
Data updated 19 hours agoSource updated unknown3 authority · jurisdiction pairs ingested
Feed
Latest approval date first; records without a date are listed last. Filters combine.
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Sep 16, 2025 | Filgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as FILRA (DIN 02556537) under ATC L03AA02 FILGRASTIM. Indications are not published in the Drug Product Database — see… | DIN02556537 | approvedsource: Marketed | health-canada-dpd |
| Sep 9, 2025 | Pegfilgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as PEXEGRA (DIN 02553945) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02553945 | approvedsource: Marketed | health-canada-dpd |
| Sep 8, 2025 | Bosutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-BOSUTINIB (DIN 02560046) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product… | DIN02560046 | approvedsource: Marketed | health-canada-dpd |
| Sep 8, 2025 | Bosutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-BOSUTINIB (DIN 02560038) under ATC L01EA04 BOSUTINIB. Indications are not published in the Drug Product… | DIN02560038 | approvedsource: Marketed | health-canada-dpd |
| Sep 8, 2025 | Bendamustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BENDAMUSTINE HYDROCHLORIDE FOR INJECTION (DIN 02541998) under ATC L01AA09 BENDAMUSTINE. Indications are not published… | DIN02541998 | approvedsource: Marketed | health-canada-dpd |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Aug 14, 2025 | Retifanlimab | Health Canada CA | cancer not stated in this record | Marketed in Canada as ZYNYZ (DIN 02555239) under ATC L01FF10 RETIFANLIMAB. Indications are not published in the Drug Product Database — see… | DIN02555239 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jul 22, 2025 | Anastrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as AG-ANASTROZOLE TABLETS (DIN 02553686) under ATC L02BG03 ANASTROZOLE. Indications are not published in the Drug… | DIN02553686 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jun 25, 2025 | Thiotepa | Health Canada CA | cancer not stated in this record | Marketed in Canada as TEPADINA (DIN 02523906) under ATC L01AC01 THIOTEPA. Indications are not published in the Drug Product Database — see… | DIN02523906 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| May 27, 2025 | Arsenic Trioxide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ARSENIC TRIOXIDE FOR INJECTION (DIN 02554364) under ATC L01XX27 ARSENIC TRIOXIDE. Indications are not published in… | DIN |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Apr 28, 2025 | Lazertinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LAZCLUZE (DIN 02555972) under ATC L01EB09 LAZERTINIB. Indications are not published in the Drug Product Database —… | DIN02555972 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Mar 4, 2025 | Talquetamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as TALVEY (DIN 02547406) under ATC L01FX29 TALQUETAMAB. Indications are not published in the Drug Product Database — see… | DIN02547406 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Feb 13, 2025 | Nilotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-NILOTINIB (DIN 02550903) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database… | DIN02550903 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Jan 31, 2025 | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-AFATINIB (DIN 02517035) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database —… | DIN02517035 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Dec 2, 2024 | Avapritinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AYVAKYT (DIN 02551799) under ATC L01EX18 AVAPRITINIB. Indications are not published in the Drug Product Database —… | DIN02551799 |
| Date | Drug | Authority · jurisdiction | Cancer | Indication (as published) | Type | Status | Source |
|---|---|---|---|---|---|---|---|
| Nov 28, 2024 | Tarlatamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMDELLTRA (DIN 02551578) under ATC L01FX33 TARLATAMAB. Indications are not published in the Drug Product Database —… | DIN02551578 |
A record is one authority's decision for one application/DIN; the same molecule appears once per jurisdiction and indication. Health Canada DPD does not publish indications — its records state the brand, DIN and ATC class only, and a cancelled or dormant DIN is the status of one product, not of the molecule. FDA cancer mappings come from label text and are flagged probabilistic on the drug page.
| approvedsource: Marketed |
| health-canada-dpd |
| Aug 11, 2025 | Belantamab Mafodotin | Health Canada CA | cancer not stated in this record | Marketed in Canada as BLENREP (DIN 02559625) under ATC L01FX15 BELANTAMAB MAFODOTIN. Indications are not published in the Drug Product… | DIN02559625 | approvedsource: Marketed | health-canada-dpd |
| Aug 11, 2025 | Belantamab Mafodotin | Health Canada CA | cancer not stated in this record | Marketed in Canada as BLENREP (DIN 02559617) under ATC L01FX15 BELANTAMAB MAFODOTIN. Indications are not published in the Drug Product… | DIN02559617 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jul 21, 2025 | Bortezomib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BORTEZOMIB INJECTION (DIN 02550075) under ATC L01XG01 BORTEZOMIB. Indications are not published in the Drug Product… | DIN02550075 | approvedsource: Marketed | health-canada-dpd |
| Jul 14, 2025 | Pazopanib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AURO-PAZOPANIB (DIN 02552957) under ATC L01EX03 PAZOPANIB. Indications are not published in the Drug Product Database… | DIN02552957 | approvedsource: Marketed | health-canada-dpd |
| Jul 11, 2025 | Eribulin | Health Canada CA | cancer not stated in this record | Marketed in Canada as ERIBULIN MESYLATE INJECTION (DIN 02545950) under ATC L01XX41 ERIBULIN. Indications are not published in the Drug… | DIN02545950 | approvedsource: Marketed | health-canada-dpd |
| withdrawnsource: Dormantsince Jul 31, 2026 |
| health-canada-dpd |
| Jun 20, 2025 | Etoposide | Health Canada CA | cancer not stated in this record | Marketed in Canada as ETOPOSIDE INJECTION (DIN 02552671) under ATC L01CB01 ETOPOSIDE. Indications are not published in the Drug Product… | DIN02552671 | approvedsource: Marketed | health-canada-dpd |
| Jun 10, 2025 | Methotrexate | Health Canada CA | cancer not stated in this record | Marketed in Canada as JAMP METHOTREXATE TABLETS (DIN 02553740) under ATC L01BA01 METHOTREXATE. Indications are not published in the Drug… | DIN02553740 | approvedsource: Marketed | health-canada-dpd |
| Jun 6, 2025 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION USP (DIN 02546744) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published… | DIN02546744 | approvedsource: Marketed | health-canada-dpd |
| Jun 6, 2025 | Cyclophosphamide | Health Canada CA | cancer not stated in this record | Marketed in Canada as CYCLOPHOSPHAMIDE FOR INJECTION USP (DIN 02546736) under ATC L01AA01 CYCLOPHOSPHAMIDE. Indications are not published… | DIN02546736 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| May 21, 2025 | Zanubrutinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as BRUKINSA (DIN 02554267) under ATC L01EL03 ZANUBRUTINIB. Indications are not published in the Drug Product Database —… | DIN02554267 | approvedsource: Marketed | health-canada-dpd |
| May 16, 2025 | Talazoparib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TALZENNA (DIN 02555050) under ATC L01XK04 TALAZOPARIB. Indications are not published in the Drug Product Database —… | DIN02555050 | approvedsource: Marketed | health-canada-dpd |
| May 16, 2025 | Talazoparib | Health Canada CA | cancer not stated in this record | Marketed in Canada as TALZENNA (DIN 02492032) under ATC L01XK04 TALAZOPARIB. Indications are not published in the Drug Product Database —… | DIN02492032 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Apr 28, 2025 | Lazertinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as LAZCLUZE (DIN 02555964) under ATC L01EB09 LAZERTINIB. Indications are not published in the Drug Product Database —… | DIN02555964 | approvedsource: Marketed | health-canada-dpd |
| Apr 25, 2025 | Letrozole | Health Canada CA | cancer not stated in this record | Marketed in Canada as M-LETROZOLE (DIN 02549972) under ATC L02BG04 LETROZOLE. Indications are not published in the Drug Product Database —… | DIN02549972 | approvedsource: Marketed | health-canada-dpd |
| Apr 24, 2025 | Nilotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-NILOTINIB (DIN 02556642) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product… | DIN02556642 | approvedsource: Marketed | health-canada-dpd |
| Apr 24, 2025 | Nilotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as REDDY-NILOTINIB (DIN 02556634) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product… | DIN02556634 | approvedsource: Marketed | health-canada-dpd |
| Apr 14, 2025 | Carmustine | Health Canada CA | cancer not stated in this record | Marketed in Canada as BICNU (DIN 02555093) under ATC L01AD01 CARMUSTINE. Indications are not published in the Drug Product Database — see… | DIN02555093 | withdrawnsource: Cancelled Post Marketsince Mar 11, 2026 | health-canada-dpd |
| Apr 10, 2025 | Inavolisib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ITOVEBI (DIN 02555484) under ATC L01EM06 INAVOLISIB. Indications are not published in the Drug Product Database — see… | DIN02555484 | approvedsource: Marketed | health-canada-dpd |
| Apr 10, 2025 | Inavolisib | Health Canada CA | cancer not stated in this record | Marketed in Canada as ITOVEBI (DIN 02555476) under ATC L01EM06 INAVOLISIB. Indications are not published in the Drug Product Database — see… | DIN02555476 | approvedsource: Marketed | health-canada-dpd |
| Apr 10, 2025 | Cabazitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as CABAZITAXEL FOR INJECTION (DIN 02553791) under ATC L01CD04 CABAZITAXEL. Indications are not published in the Drug… | DIN02553791 | approvedsource: Marketed | health-canada-dpd |
| Apr 10, 2025 | Cabazitaxel | Health Canada CA | cancer not stated in this record | Marketed in Canada as CABAZITAXEL FOR INJECTION (DIN 02553783) under ATC L01CD04 CABAZITAXEL. Indications are not published in the Drug… | DIN02553783 | approvedsource: Marketed | health-canada-dpd |
| Apr 1, 2025 | Zolbetuximab | Health Canada CA | cancer not stated in this record | Marketed in Canada as VYLOY (DIN 02553996) under ATC L01FX31 ZOLBETUXIMAB. Indications are not published in the Drug Product Database — see… | DIN02553996 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Mar 4, 2025 | Talquetamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as TALVEY (DIN 02547392) under ATC L01FX29 TALQUETAMAB. Indications are not published in the Drug Product Database — see… | DIN02547392 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Feb 13, 2025 | Nilotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as APO-NILOTINIB (DIN 02550881) under ATC L01EA03 NILOTINIB. Indications are not published in the Drug Product Database… | DIN02550881 | approvedsource: Marketed | health-canada-dpd |
| Feb 12, 2025 | Pegfilgrastim | Health Canada CA | cancer not stated in this record | Marketed in Canada as NIOPEG (DIN 02546973) under ATC L03AA13 PEGFILGRASTIM. Indications are not published in the Drug Product Database —… | DIN02546973 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Jan 31, 2025 | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-AFATINIB (DIN 02517027) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database —… | DIN02517027 | approvedsource: Marketed | health-canada-dpd |
| Jan 31, 2025 | Afatinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as MAR-AFATINIB (DIN 02517019) under ATC L01EB03 AFATINIB. Indications are not published in the Drug Product Database —… | DIN02517019 | approvedsource: Marketed | health-canada-dpd |
| Jan 21, 2025 | Momelotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as OJJAARA (DIN 02552981) under ATC L01EJ04 MOMELOTINIB. Indications are not published in the Drug Product Database —… | DIN02552981 | approvedsource: Marketed | health-canada-dpd |
| Jan 21, 2025 | Momelotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as OJJAARA (DIN 02552973) under ATC L01EJ04 MOMELOTINIB. Indications are not published in the Drug Product Database —… | DIN02552973 | approvedsource: Marketed | health-canada-dpd |
| Jan 21, 2025 | Momelotinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as OJJAARA (DIN 02552965) under ATC L01EJ04 MOMELOTINIB. Indications are not published in the Drug Product Database —… | DIN02552965 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Dec 2, 2024 | Avapritinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AYVAKYT (DIN 02551780) under ATC L01EX18 AVAPRITINIB. Indications are not published in the Drug Product Database —… | DIN02551780 | approvedsource: Marketed | health-canada-dpd |
| Dec 2, 2024 | Avapritinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AYVAKYT (DIN 02551772) under ATC L01EX18 AVAPRITINIB. Indications are not published in the Drug Product Database —… | DIN02551772 | approvedsource: Marketed | health-canada-dpd |
| Dec 2, 2024 | Avapritinib | Health Canada CA | cancer not stated in this record | Marketed in Canada as AYVAKYT (DIN 02551764) under ATC L01EX18 AVAPRITINIB. Indications are not published in the Drug Product Database —… | DIN02551764 | approvedsource: Marketed | health-canada-dpd |
| approvedsource: Marketed |
| health-canada-dpd |
| Nov 28, 2024 | Tarlatamab | Health Canada CA | cancer not stated in this record | Marketed in Canada as IMDELLTRA (DIN 02551551) under ATC L01FX33 TARLATAMAB. Indications are not published in the Drug Product Database —… | DIN02551551 | approvedsource: Marketed | health-canada-dpd |
| Nov 19, 2024 | Lisocabtagene Maraleucel | Health Canada CA | cancer not stated in this record | Marketed in Canada as BREYANZI (DIN 02527138) under ATC L01XL08 LISOCABTAGENE MARALEUCEL. Indications are not published in the Drug Product… | DIN02527138 | approvedsource: Marketed | health-canada-dpd |